Missed Review Deadlines Are Reminder That On-Time Approvals Are A Goal, Not A Guarantee
Executive Summary
After more than a decade of sky-high rates of on-time regulatory action by the US FDA, missed user fee goal dates are back in a pretty big way – and it’s not just JAK inhibitor and COVID-19 delays.
You may also be interested in...
Sanofi/Regeneron’s Esophagitis Data Add To Dupixent’s Winning Streak
The companies announced positive Phase III data for the drug in patients with eosinophilic esophagitis and plan to take the results to regulators in 2022.
Delay Looms For Axsome Therapeutics’ Entry Into Major Depressive Disorder Market With Lead Product
Axsome Therapeutics’ lead candidate, AXS-05, was nearing the US market for major depressive disorder, but the US company is trying to find out more about deficiencies identified by US regulators; the biotech has also reported positive Phase II results in treatment-resistant depression.
Keeping Track: US FDA Clears Opioid Seglentis And Anti-Opioid Zimhi; CRLs For Revance, United; Delay For UCB
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker